Status:
TERMINATED
A Study of the Pharmacokinetics/Pharmacodynamics of GK Activator (2) in Type 2 Diabetes Patients With Hepatic Impairment.
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
This study will investigate the effect of hepatic impairment on the pharmacokinetics, pharmacodynamics, safety and tolerability of GK Activator (2) in type 2 diabetes patients with mild and moderate h...
Eligibility Criteria
Inclusion
- adult patients, 18-75 years of age;
- type 2 diabetes;
- normal hepatic function, or mild or moderate hepatic impairment.
Exclusion
- type 1 diabetes, or latent autoimmune diabetes in adults;
- diabetic neuropathy, retinopathy or nephropathy;
- treatment with insulin or PPAR gamma agonist within 6 weeks of screening;
- clinically significant cardiovascular disease.
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT00437606
Start Date
March 1 2007
End Date
June 1 2007
Last Update
August 24 2016
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Berlin, Germany
2
Kiel, Germany
3
Bratislava, Slovakia